<DOC>
	<DOCNO>NCT02540954</DOCNO>
	<brief_summary>To compare efficacy 2 mg aflibercept administer two different intravitreal ( IVT ) treatment regimens subject neovascular age-related macular degeneration ( nAMD )</brief_summary>
	<brief_title>Efficacy Safety Two Different Aflibercept Regimens Subjects With Neovascular Age-related Macular Degeneration ( nAMD )</brief_title>
	<detailed_description>330 Patients complete least one year treatment aflibercept randomize two different aflibercept regimen follow 76 week .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>The following criterion must meet initial start aflibercept treatment ( i.e . start aflibercept treatment least 1 year study ) : Subject primary subfoveal choroidal neovascularization ( CNV ) lesion secondary nAMD , include juxtafoveal lesion affect fovea , evidence fluorescein angiography/photography ( FA/FP ) study eye within 3 week initiation aflibercept treatment . The area CNV occupy least 50 % total lesion within 3 week initiation aflibercept treatment . Documented bestcorrected visual acuity ( BCVA ) 20/40 20/320 ( letter score 73 25 ) study eye initiation treatment . Men woman &gt; = 51 year age The subject 's history aflibercept treatment meet ALL following : Treatment study eye initiate three monthly ( 1 week/+2 week ) dose 2 mg aflibercept improvement visual anatomic outcome observe Following initiation phase , interval treatment 6 week 12 week Any prior concomitant therapy investigational approve agent treat neovascular AMD study eye aflibercept . Total lesion size &gt; 12 disc area ( 30.5 mm2 , include blood , scar neovascularization ) assess fluorescein angiography ( FA ) study eye Subretinal hemorrhage : 1 . 50 % total lesion area , 2. blood fovea , 3. blood fovea 1 disc area size study eye . Scar fibrosis make 50 % total lesion study eye . Scar , fibrosis , atrophy involve center fovea study eye . Presence retinal pigment epithelial tear rip involve macula study eye . Causes CNV AMD study eye .</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Age-related macular degeneration ( AMD )</keyword>
	<keyword>Eylea treatment</keyword>
	<keyword>Treat Extend</keyword>
	<keyword>Intravitreal</keyword>
</DOC>